Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: A retrospective study
- Autori: Cicero, G.; DE LUCA, R.; Blasi, L.; Pepe, A.; Pavone, C.; Simonato, A.; Dieli, F.
- Anno di pubblicazione: 2017
- Tipologia: Articolo in rivista (Articolo in rivista)
- Parole Chiave: abiraterone; androgen antagonists; drug therapy; metastatic castration-resistant prostate cancer; prostatic neoplasms; Oncology; Pharmacology; Pharmacology (medical); Cancer Research
- OA Link: http://hdl.handle.net/10447/244652
The aim of this study was to evaluate abiraterone's efficacy in Italian patients affected with metastatic prostate cancer progressing after treatment with docetaxel. We conducted a retrospective analysis of 60 patients. Prostate-specific antigen (PSA) reduction in serum was the primary endpoint for evaluating the efficacy of abiraterone in combination with prednisone treatment, whereas reduced pain, safety, progression-free survival, response rate, and overall survival (OS) were secondary endpoints. A significant correlation was noticed between PSA response and OS. Further, the Index Bravais-Pearson (r) correlation allowed us to observe a significant negative interdependence between PSA response and reduction in pain of 0.57 (95% confidence interval:-0.30 to 0.80) (P=0.005). Meanwhile, regression analysis revealed that PSA levels are predictive of OS. There was a positive correlation with OS, which showed a value of R 2 to 0.50 with a slope of 1.44 (P=0.0021). Abiraterone is a well-Tolerated and effective treatment modality for patients affected with metastatic castration-resistant prostate cancer. The drug has a better tolerability profile, gives significant pain relief, and increases the survival rate.